MaxCyte, Inc. (NASDAQ:MXCT) Given Average Rating of “Hold” by Analysts

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have received a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $5.50.

A number of research analysts recently commented on MXCT shares. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Friday, April 24th. Finally, Craig Hallum reduced their price objective on MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. bought a new position in shares of MaxCyte during the second quarter valued at about $26,000. State of Wyoming bought a new position in shares of MaxCyte during the second quarter valued at about $38,000. BNP Paribas Financial Markets grew its stake in shares of MaxCyte by 266.6% during the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after buying an additional 18,913 shares during the last quarter. Jain Global LLC bought a new position in shares of MaxCyte during the fourth quarter valued at about $45,000. Finally, Virtu Financial LLC bought a new position in shares of MaxCyte during the fourth quarter valued at about $67,000. 68.81% of the stock is owned by institutional investors.

MaxCyte Stock Down 4.6%

MXCT opened at $1.04 on Friday. The stock has a market cap of $111.41 million, a PE ratio of -2.81 and a beta of 1.37. MaxCyte has a 52 week low of $0.64 and a 52 week high of $2.40. The business’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $1.14.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Tuesday, May 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. The business had revenue of $6.22 million for the quarter, compared to analysts’ expectations of $7.28 million. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%. As a group, equities analysts anticipate that MaxCyte will post -0.3 earnings per share for the current year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.